-
Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy
Previously Published on Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Lineage Cell Therapeutics Inc. (AMEX: LCTX) recently provided an update on its lead program OpRegen®, a cell replacement therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA). Lineage is pioneering a new branch of medicine, which is manufacturing differentiated cell types and transplanting those cells into the body, to restore or improve function which has been lost due to injury or disease. The data from an ongoing Phase 1/2a clinical study continued to demonstrate that a single administration of OpRegen, an investigational cell therapy consisting of…
You May Also Like
Biotricity Invites Physicians to Join Shared Revenue Opportunity, Provides Clinics with Remote Devices for Improved Monitoring and Diagnosis
MedTech Company BioSig Technologies Deploys Disruptive Technology To Improve Arrhythmia Care
Biotricity Reports Q1 Earnings at 290% for FY2022
-
How and why Shorty Produkshins is shifting gears in 2016
As many of you must know, the face of SEO and Internet Marketing is rapidly changing. It’s been almost ten years since we completely evolved into a marketing company. True, we still made music clean up into 2010, but this was done through subsidiary, Shorty’s Playground, after splitting into two separate entities in 2007. Shorty Produkshins has prided itself on keeping ahead of the competition by being early adopters and evolving our services to meet the needs of our growing audiences. We started as that tiny little studio, consisting of a computer and a closet, and delivered many phases to our most avid supporters. Many of you remember our plaza…
